Regenerative medicine最新文献

筛选
英文 中文
iPSC stem cell banks: is it really necessary if we already have cord blood banks? iPSC干细胞库:如果我们已经有了脐带血库,真的有必要吗?
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2025-01-01 Epub Date: 2025-01-16 DOI: 10.1080/17460751.2025.2453332
David T Harris, Michael Badowski
{"title":"iPSC stem cell banks: is it really necessary if we already have cord blood banks?","authors":"David T Harris, Michael Badowski","doi":"10.1080/17460751.2025.2453332","DOIUrl":"10.1080/17460751.2025.2453332","url":null,"abstract":"","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"17-20"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research advance of 3D printing for articular cartilage regeneration. 3D打印用于关节软骨再生的研究进展。
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2025-01-01 Epub Date: 2025-02-17 DOI: 10.1080/17460751.2025.2466346
Haicheng Tao, Mingli Feng, Hui Feng, Hongchen Ren
{"title":"Research advance of 3D printing for articular cartilage regeneration.","authors":"Haicheng Tao, Mingli Feng, Hui Feng, Hongchen Ren","doi":"10.1080/17460751.2025.2466346","DOIUrl":"10.1080/17460751.2025.2466346","url":null,"abstract":"<p><p>Articular cartilage lesion frequently leads to dysfunction and the development of degenerative diseases, posing a significant public health challenge due to the limited self-healing capacity of cartilage tissue. Current surgical treatments, including marrow stimulation techniques and osteochondral autografts/allografts, have limited efficacy or have significant drawbacks, highlighting the urgent need for alternative strategies. Advances in 3D printing for cartilage regeneration have shown promising potential in creating cartilage-mimicking constructs, thereby opening new possibilities for cartilage repair. In this review, we summarize current surgical treatment methods and their limitations for addressing articular cartilage lesion, various 3D printing strategies and their features in cartilage tissue engineering, seed cells from different sources, and different types of biomaterials. We also explore the benefits, current challenges, and future research directions for 3D printing in the treatment of articular cartilage lesion within the field of cartilage tissue engineering.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"45-55"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BMSC-derived exosomes improve rheumatoid arthritis by regulating Th17 cell differentiation through targeting PRDM1. bmsc衍生外泌体通过靶向PRDM1调控Th17细胞分化改善类风湿关节炎。
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2025-01-01 Epub Date: 2025-03-01 DOI: 10.1080/17460751.2025.2469426
Shaomin Chen, Xinxin Li, Yang Shen, Shichong Lin, Xiaolong Shui, Hua Zhu
{"title":"BMSC-derived exosomes improve rheumatoid arthritis by regulating Th17 cell differentiation through targeting PRDM1.","authors":"Shaomin Chen, Xinxin Li, Yang Shen, Shichong Lin, Xiaolong Shui, Hua Zhu","doi":"10.1080/17460751.2025.2469426","DOIUrl":"10.1080/17460751.2025.2469426","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is categorized as an autoimmune condition. Bone marrow-derived mesenchymal stromal cell (BMSC) derived exosome (BMSC-Exo) exert vital character in RA. We aimed to investigate the regulatory mechanism of BMSC-Exo in alleviating RA.</p><p><strong>Methods: </strong>BMSC was isolated from mouse bone marrow. Collagen-induced arthritis (CIA) was induced by injecting bovine type II collagen and complete Freund's adjuvant. Arthritis score, incidence, and withdrawal threshold were assessed. Hematoxylin-eosin staining was used to observe knee joint damage. CD4<sup>+</sup> T cells were isolated from the spleen, and T helper 17 (Th17) proportions were measured by flow cytometry. Caspase-1 activity was assessed.</p><p><strong>Results: </strong>BMSC-Exo injection reduced arthritis score and incidence of arthritis, and elevated the withdrawal threshold of CIA mice. BMSC-Exo also alleviated knee damage in CIA mice and reduced the Th17 proportion. BMSC-Exo down-regulated inflammatory cytokine levels, as well as caspase-1 activity. BMSC-Exo up-regulated PR Domain Zinc Finger Protein 1 (PRDM1) levels. PRDM1 knockdown in BMSC down-regulated PRDM1 expression in Exo but did not affect up-regulated PRDM1 expression in CD4<sup>+</sup> T cells. In vivo, BMSC-Exo affected RA pathology by acting on PRDM1.</p><p><strong>Conclusions: </strong>BMSC-Exo improved RA by promoting PRDM1 expression in CD4<sup>+</sup> T cells and inhibiting Th17 cell differentiation.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"35-44"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11881839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence powers regenerative medicine into predictive realm. 人工智能推动再生医学进入预测领域。
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2024-12-01 Epub Date: 2024-12-11 DOI: 10.1080/17460751.2024.2437281
Armin Garmany, Andre Terzic
{"title":"Artificial intelligence powers regenerative medicine into predictive realm.","authors":"Armin Garmany, Andre Terzic","doi":"10.1080/17460751.2024.2437281","DOIUrl":"10.1080/17460751.2024.2437281","url":null,"abstract":"<p><p>The expanding regenerative medicine toolkit is reaching a record number of lives. There is a pressing need to enhance the precision, efficiency, and effectiveness of regenerative approaches and achieve reliable outcomes. While regenerative medicine has relied on an empiric paradigm, availability of big data along with advances in informatics and artificial intelligence offer the opportunity to inform the next generation of regenerative sciences along the discovery, translation, and application pathway. Artificial intelligence can streamline discovery and development of optimized biotherapeutics by aiding in the interpretation of readouts associated with optimal repair outcomes. In advanced biomanufacturing, artificial intelligence holds potential in ensuring quality control and assuring scalability through automated monitoring of process-critical variables mandatory for product consistency. In practice application, artificial intelligence can guide clinical trial design, patient selection, delivery strategies, and outcome assessment. As artificial intelligence transforms the regenerative horizon, caution is necessary to reduce bias, ensure generalizability, and mitigate ethical concerns with the goal of equitable access for patients and populations.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"611-616"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703382/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allogeneic bone marrow derived clonal mesenchymal stromal cells in refractory rheumatoid arthritis: a pilot study. 难治性类风湿关节炎中的同种异体骨髓衍生克隆间充质基质细胞:一项初步研究。
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2024-12-01 Epub Date: 2024-12-23 DOI: 10.1080/17460751.2024.2443352
Ahmadreza Jamshidi, Alireza Beheshti Maal, Majid Alikhani, Hoda Madani, Bahareh Sadri, Maryam Moghaddassi, Ahmad Salimzadeh, Mahtab Ahmadipour, Mohammad Amin Shahrbaf, Ensiyeh Hajizadeh-Saffar, Mohamadreza Baghaban Eslaminejad, Seyedeh-Nafiseh Hassani, Leila Taghiyar, Fatemeh Abbasi, Hossein Baharvand, Massoud Vosough
{"title":"Allogeneic bone marrow derived clonal mesenchymal stromal cells in refractory rheumatoid arthritis: a pilot study.","authors":"Ahmadreza Jamshidi, Alireza Beheshti Maal, Majid Alikhani, Hoda Madani, Bahareh Sadri, Maryam Moghaddassi, Ahmad Salimzadeh, Mahtab Ahmadipour, Mohammad Amin Shahrbaf, Ensiyeh Hajizadeh-Saffar, Mohamadreza Baghaban Eslaminejad, Seyedeh-Nafiseh Hassani, Leila Taghiyar, Fatemeh Abbasi, Hossein Baharvand, Massoud Vosough","doi":"10.1080/17460751.2024.2443352","DOIUrl":"10.1080/17460751.2024.2443352","url":null,"abstract":"<p><strong>Aims: </strong>This phase I trial assessed the safety and potential efficacy of monthly 3 dose intravenous infusion of allogeneic bone marrow-derived clonal mesenchymal stromal cells (BM-cMSCs) in refractory rheumatoid arthritis (RA) patients over 24 weeks.</p><p><strong>Patients & methods: </strong>Six patients with refractory RA received BM-cMSC infusions at one-month intervals over a 24-week period. Safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Clinical efficacy was assessed using the Visual Analog Scale (VAS), Simple and Clinical Disease Activity Indices (SDAI/CDAI), Health Assessment Questionnaire (HAQ), and American College of Rheumatology (ACR) response criteria. Serological makers including: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), IL-10, IL-17, TNF-α, and Treg/Th17 ratios were measured.</p><p><strong>Results: </strong>BM-cMSC infusions were well-tolerated, with no SAEs reported. VAS scores improved in three patients, with two achieving sustained pain relief and quality-of-life enhancement. Four patients met ACR20 at week 16, while SDAI and CDAI scores indicated disease activity reduction in three patients. Anti-CCP and RF levels showed variable responses, with some increases not consistently correlating with clinical outcomes. Serological biomarkers showed mixed results; IL-10 increased in five patients, while pro-inflammatory markers TNF-α and IL-17 decreased in the same individuals.</p><p><strong>Conclusions: </strong>BM-cMSC therapy demonstrated a favorable safety profile and potential efficacy in managing refractory RA. While preliminary results are promising, further studies with larger cohorts and long-term follow-up are needed to validate these findings and optimize therapeutic strategies.</p><p><strong>Clinical trial registration: </strong>IRCT20080728001031N29.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"599-609"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Industry updates from the field of stem cell research and regenerative medicine in August 2024. 2024 年 8 月干细胞研究和再生医学领域的行业动态。
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2024-12-01 Epub Date: 2024-11-04 DOI: 10.1080/17460751.2024.2418246
Dusko Ilic, Mirjana Liovic
{"title":"Industry updates from the field of stem cell research and regenerative medicine in August 2024.","authors":"Dusko Ilic, Mirjana Liovic","doi":"10.1080/17460751.2024.2418246","DOIUrl":"10.1080/17460751.2024.2418246","url":null,"abstract":"<p><p>Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in August 2024.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"581-587"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in the processing and preservation of adipose-derived stem cell subpopulations for clinical use. 处理和保存用于临床的脂肪来源干细胞亚群所面临的挑战。
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2024-12-01 Epub Date: 2024-12-20 DOI: 10.1080/17460751.2024.2442843
Qiuyue Peng
{"title":"Challenges in the processing and preservation of adipose-derived stem cell subpopulations for clinical use.","authors":"Qiuyue Peng","doi":"10.1080/17460751.2024.2442843","DOIUrl":"10.1080/17460751.2024.2442843","url":null,"abstract":"","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"595-597"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk-based pricing models and the role they might play in patients' access to new stem cell therapies. 基于风险的定价模型及其在患者获得新的干细胞疗法方面可能发挥的作用。
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2024-12-01 Epub Date: 2024-12-18 DOI: 10.1080/17460751.2024.2441642
Klaus Hoeyer, Anne Sofie Borsch, Kim Bak Jensen, Agnete Kirkeby, Casper Steenholdt, Sarah Wadmann
{"title":"Risk-based pricing models and the role they might play in patients' access to new stem cell therapies.","authors":"Klaus Hoeyer, Anne Sofie Borsch, Kim Bak Jensen, Agnete Kirkeby, Casper Steenholdt, Sarah Wadmann","doi":"10.1080/17460751.2024.2441642","DOIUrl":"10.1080/17460751.2024.2441642","url":null,"abstract":"<p><p>Stem cell research is currently undergoing a promising transformation from primarily basic research to increasing emphasis on translation and clinical trials. To reach patients, however, stem cell treatments need to be not only technically but also economically viable. In this commentry we present insights into emerging pricing models that may help ensure access to advanced and expensive treatments like stem cell therapies. Further, we present some reflections on the practical and ethical challenges that these models involve. We provide this information to allow the field of translational stem cell research to think ahead and to raise awareness of the outstanding social and ethical issues.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"589-593"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular vesicles as standard-of-care therapy: will fast-tracking the regulatory processes help achieve the goal? 细胞外囊泡作为标准疗法:加快监管进程是否有助于实现目标?
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2024-12-01 Epub Date: 2024-12-17 DOI: 10.1080/17460751.2024.2442847
Vaijayanti Kale
{"title":"Extracellular vesicles as standard-of-care therapy: will fast-tracking the regulatory processes help achieve the goal?","authors":"Vaijayanti Kale","doi":"10.1080/17460751.2024.2442847","DOIUrl":"10.1080/17460751.2024.2442847","url":null,"abstract":"<p><p>Extracellular Vesicles (EVs) became a focus of clinical research when experimental and pre-clinical studies showed that they mimic their parent cells' regenerative and therapeutic effects and their cargo carries disease-specific diagnostic and prognostic biomarkers. Since the publication of data forms an endpoint of the study, this review specifically focused on the <i>published clinical trials</i> done with EVs. For brevity, this review was restricted to the last 10 years. Unexpectedly, the literature search showed that very few clinical trials assessing the therapeutic applications of EVs were published in this period indicating that they have not reached their desired endpoint. Conversely, most studies showed the potential of EVs present in various biofluids as a promising source of diagnostic and prognostic biomarkers for various diseases, and predictive markers to assess the effectiveness of therapy. This stark difference in the numbers could perhaps be due to the time-consuming regulatory processes involved in the clinical-grade preparation and characterization of EVs, and the determination of their safety and effective dose regimens. One wonders whether fast-tracking regulatory affairs could help accelerate the therapeutic use of EVs. This aspect needs urgent attention.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"617-635"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intra-articular hyaluronic acid and platelet-rich plasma as monotherapy or combination therapy in knee osteoarthritis? 关节内透明质酸和富血小板血浆是治疗膝骨关节炎的单一疗法还是联合疗法?
IF 2.4 4区 医学
Regenerative medicine Pub Date : 2024-12-01 Epub Date: 2024-12-11 DOI: 10.1080/17460751.2024.2439221
Sheng-Fei Oon, Smaro Lazarakis, Gayani Mallawa, Chau Nguyen
{"title":"Intra-articular hyaluronic acid and platelet-rich plasma as monotherapy or combination therapy in knee osteoarthritis?","authors":"Sheng-Fei Oon, Smaro Lazarakis, Gayani Mallawa, Chau Nguyen","doi":"10.1080/17460751.2024.2439221","DOIUrl":"10.1080/17460751.2024.2439221","url":null,"abstract":"<p><strong>Aim: </strong>To systematically identify best current evidence on intra-articular combination therapy with hyaluronic acid (HA) and platelet-rich plasma (PRP), compared to monotherapy in knee osteoarthritis.</p><p><strong>Methods: </strong>Using the McMaster University and National Health Service five-step systematic approach, we conducted a bottom-up literature search of all existing evidence through Ovid Medline, Ovid Embase, and Cochrane (Central - Wiley) from January 2021 to June 2024.</p><p><strong>Results: </strong>Of 258 articles retrieved, we systematically narrowed best current evidence to one meta-analysis when evaluating combination therapy versus HA alone. This demonstrated superior outcomes with combination therapy against HA only at 3, 6, and 12 months on the visual acuity scale (VAS, <i>p</i> < 0.001), and with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at 12 months in areas of stiffness and physical function (<i>p</i> < 0.001). For combination therapy versus PRP alone, one randomized controlled trial qualified as best current evidence. This demonstrated superior VAS outcomes with combination therapy compared to PRP monotherapy at 6 months (<i>p</i> < 0.02).</p><p><strong>Conclusion: </strong>Best current evidence indicates that intra-articular HA and PRP as combination therapy has superior short and long term symptom control over HA or PRP as monotherapy. Due to the extensive heterogeneity in the studies, results should be interpreted with caution.</p>","PeriodicalId":21043,"journal":{"name":"Regenerative medicine","volume":" ","pages":"637-644"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信